bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® VITAMIN B12 TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B12 concentration in human serum or plasma.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know® Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food & Drug Administration (FDA) that can be performed by both physicians and patients.

Diasorin (FTSE MIB: DIA) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX® Gram-Negative Blood Culture Assay, the second of the three molecular multiplexing panels for Blood Culture identification on the LIAISON PLEX®.

Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies1. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the availability of 13 blood tests designed to evaluate micronutrient deficiencies, helping people identify if they are lacking certain vitamins and minerals needed by the body to maintain optimal health. These panels are now available for consumer purchase exclusively at questhealth.com.

Missouri-based diagnostic provider C2N has struck a deal with diagnostic services provider Unilabs to expand access to its Precivity portfolio of Alzheimer’s blood tests in over 75 countries.

Alzpath said Monday that it has signed a licensing agreement with Beckman Coulter Diagnostics for use of the Alzpath phosphorylated-tau 217 antibody in a blood-based test for Alzheimer's disease.

A workgroup convened by the Alzheimer’s Association has published revised criteria for the diagnosis and staging of Alzheimer’s disease that are based on the biology of the disease and reflect recent advancements in Alzheimer’s research, diagnostics and treatment. The 2024 update includes an updated biomarker classification system that includes blood-based biomarkers (BBM) and a revised disease staging system.

With the help of proteomic profiling and machine learning, an international team led by investigators in the UK and Germany has identified a handful of blood plasma proteins associated with subsequent Parkinson's disease development, pointing to the possibility of developing blood-based biomarkers for the progressive neurodegenerative condition.

Siemens Healthineers said on Monday that the firm has received CE marking for a prognostic blood test that the firm plans to launch later this year in Europe to aid the management of multiple sclerosis.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada. The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.